{"id":"W2787266690","doi":"10.1016/j.ygyno.2018.01.019","title":"Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer","year":2018,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"Astellas Pharma","keywords":"Medicine; Paclitaxel; Tolerability; Internal medicine; Clinical endpoint; Ovarian cancer; Adverse effect; Oncology; Discontinuation; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Urology; Phases of clinical research; Gastroenterology; Cancer; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001710916,0.001647951,0.003443135,0.0007723792,0.0005401786,0.001104203,0.001296992,0.001506692,0.005764888],"category_scores_gemma":[0.00146126,0.001002742,0.001889782,0.0007583061,0.001427106,0.001426126,0.0004864621,0.004389162,0.0009097609],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001282541,"about_ca_system_score_gemma":0.002141725,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002293163,"about_ca_topic_score_gemma":0.004614717,"domain_scores_codex":[0.999298,0.0003341865,0.00003283692,0.0001452588,0.00004607336,0.0001436169],"domain_scores_gemma":[0.9987287,0.000277204,0.0002004159,0.0001594768,0.0000581549,0.0005761949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8895591,0.04981078,0.003515485,0.0002599262,0.0008286071,0.00009178053,0.0001836865,0.001307944,0.01200148,0.0001114651,0.0009979747,0.04133182],"study_design_scores_gemma":[0.6334487,0.3556787,0.007334257,0.00001105079,0.0003726099,0.00008945111,0.00005389273,0.0006566411,0.001227165,0.00009209304,0.001013247,0.00002216591],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951056,0.0009408015,0.0003803122,0.000306143,0.0001049898,0.00141755,0.0006872723,0.00008317494,0.0009741107],"genre_scores_gemma":[0.9898961,0.00107674,0.001524027,0.0006037171,0.0002613628,0.002548895,0.001516755,0.00004685655,0.00252557],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005764888,"threshold_uncertainty_score":0.0192855,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0326541113957711,"score_gpt":0.3527039054452852,"score_spread":0.3200497940495141,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}